NEW
Stock Screener with Intrinsic Value
Protagonist Therapeutics, Inc. (PTGX)
Last Price$37.2(1.6%)
Market Cap$2,297.8M
LTM NOPAT
$150.8M
NOPAT margin
46.6%
5Y avg: (2,907.1%)
EPV as % of EV
65.3%
Market-Implied Value of Growth,
MIVoG as % of EV
34.7%
Discount rate
10.6%
Stock quality
7/10
Great
PTGX Earnings Power Value Model
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
PTGX NOPAT
Crunching data... Almost there!
PTGX Earnings Power Value and Enterprise Value
Crunching data... Almost there!
PTGX vs Peer Set: Earnings Power Value comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for PTGX
Reverse DCF
Intrinsic Value
Peter Lynch Fair Value
Discount rate
Earnings growth model
Relative Value
DCF value calculator
Ben Graham Fair Value
Peter Lynch charts
Margin of safety
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Protagonist Therapeutics, Inc. Earnings Power Value?
As of Sep 30, 2024, Protagonist Therapeutics, Inc.'s Earnings Power Value is approximately $1,422.1M.
What is Protagonist Therapeutics, Inc. EV (Enterprise Value)?
As of Sep 30, 2024, Protagonist Therapeutics, Inc.'s Enterprise Value (EV) estimates at $2,178.7M.
What is Protagonist Therapeutics, Inc. NOPAT?
As of Sep 30, 2024, Protagonist Therapeutics, Inc.'s Net operating profit after tax (NOPAT) is approximately $150.8M.